文献速递肾移植急性肾损伤肾小球疾病

依库珠单抗在非典型溶血性尿毒症综合征肾移植患者中的应用

Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome.
PubMed 文献 · Kidney Int Rep · 2018-12-03

基于全球aHUS登记研究1549例中344例肾移植患者,其中188例接受依库珠单抗。移植前及移植期间用药组(组1)较移植后用药组(组2)移植后5年内透析风险更低,移植后6个月内移植肾功能更好;移植后才诊断aHUS并用药者透析风险显著增加。

要点

  • 移植前及移植期间使用依库珠单抗可降低移植后透析风险并改善早期移植肾功能。
  • 移植后才诊断aHUS并启动依库珠单抗者移植后透析风险显著增加。
  • 延迟诊断与治疗与移植后透析风险增加及移植肾功能下降相关。

核心结论

  • 接受依库珠单抗治疗的aHUS肾移植患者结局优于既往未治疗报道。
  • 延迟诊断aHUS及因此延迟治疗与移植后透析风险增加和移植肾功能降低相关。

研究设计与样本

  • 全球aHUS登记研究(n=1549)中344例有至少1次肾移植,其中188例接受依库珠单抗。
  • 组1为88例(47%)在最近一次移植前及移植期间诊断aHUS并使用依库珠单抗。
  • 组2为100例(53%)移植后启动依库珠单抗,其中组2a为移植前诊断(n=52),组2b为移植后诊断(n=48)。

主要发现

  • 移植后5年内47例需要透析;组2b透析风险显著增加(HR 4.6;CI 1.7-12.4),组2a无显著增加(HR 2.3;CI 0.9-6.2)。
  • 移植后6个月内移植肾功能组1中位eGFR为60.6 ml/min per 1.73 m2,优于组2a的31.5(P=0.004)和组2b的9.6 ml/min per 1.73 m2(P=0.0001)。
  • 报告1例脑膜炎球菌感染(经治疗缓解)和3例死亡(判定与依库珠单抗无关)。

临床怎么用

  • 对确诊aHUS的肾移植候选者,可考虑在移植前及移植期间启动依库珠单抗以降低移植后透析风险。
  • 移植后应警惕aHUS延迟诊断,因其与透析风险增加和移植肾功能降低相关。

局限性

  • 为登记研究资料,非随机对照,组间比较可能受混杂影响。
  • 原文未报告全部基线特征、随访时长及统计效能等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Recurrence of atypical hemolytic uremic syndrome (aHUS) in renal allografts is common, leading to dialysis and graft failure. Pretransplant versus posttransplant initiation of eculizumab treatment in patients with aHUS has not been rigorously investigated. We hypothesized eculizumab pretransplant would reduce dialysis incidence posttransplant. METHODS: Of patients enrolled in the Global aHUS Registry (n = 1549), 344 had ≥1 kidney transplant. Of these, 188 had received eculizumab. Eighty-eight patients (47%) were diagnosed with aHUS and received eculizumab before, and during, their most recent transplant (group 1). A total of 100 patients (53%; group 2) initiated eculizumab posttransplantation. This second group was subdivided into those diagnosed with aHUS before (n = 52; group 2a) or after (n = 48; group 2b) their most recent transplant. RESULTS: Within 5 years of transplantation, 47 patients required dialysis; the risk of dialysis after transplantation was significantly increased in group 2b (hazard ratio [HR] 4.6; confidence interval [CI] 1.7-12.4) but not 2a (HR 2.3; CI 0.9-6.2). Graft function within 6 months of transplantation was significantly better in group 1 (median estimated glomerular filtration rate of 60.6 ml/min per 1.73 m2) compared with 31.5 and 9.6 ml/min per 1.73 m2 in groups 2a (P = 0.004) and 2b (P = 0.0001), respectively. One meningococcal infection (resolved with treatment) and 3 deaths (deemed unrelated to eculizumab) were reported. CONCLUSIONS: Outcomes for transplant patients with aHUS treated with eculizumab were improved compared with previous reports of patients with aHUS not treated with eculizumab. Our findings suggest delayed aHUS diagnosis and therefore treatment is associated with an increased risk of dialysis posttransplantation and reduced allograft function.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Siedlecki AM, Isbel N, Vande Walle J, et al. Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome. Kidney Int Rep. 2018. PMID: 30899871. doi:10.1016/j.ekir.2018.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。